<?xml version='1.0' encoding='utf-8'?>
<document id="17931461"><sentence text="Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects."><entity charOffset="81-93" id="DDI-PubMed.17931461.s1.e0" text="vildagliptin" /><entity charOffset="98-109" id="DDI-PubMed.17931461.s1.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.17931461.s1.e0" e2="DDI-PubMed.17931461.s1.e0" /><pair ddi="false" e1="DDI-PubMed.17931461.s1.e0" e2="DDI-PubMed.17931461.s1.e1" /></sentence><sentence text="Vildagliptin is an orally active, potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4), the enzyme responsible for the degradation of incretin hormones"><entity charOffset="0-12" id="DDI-PubMed.17931461.s2.e0" text="Vildagliptin" /></sentence><sentence text=" By enhancing prandial levels of incretin hormones, vildagliptin improves glycemic control in type 2 diabetes"><entity charOffset="52-64" id="DDI-PubMed.17931461.s3.e0" text="vildagliptin" /></sentence><sentence text=" Co-administration of vildagliptin and simva statin, an HMG-CoA-reductase inhibitor may be required to treat patients with diabetes and dyslipidemia"><entity charOffset="22-34" id="DDI-PubMed.17931461.s4.e0" text="vildagliptin" /></sentence><sentence text=" There fore, this study was conducted to determine the potential for pharmacokinetic drug-drug interaction between vildagliptin and simvastatin at steady-state"><entity charOffset="115-127" id="DDI-PubMed.17931461.s5.e0" text="vildagliptin" /><entity charOffset="132-143" id="DDI-PubMed.17931461.s5.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.17931461.s5.e0" e2="DDI-PubMed.17931461.s5.e0" /><pair ddi="false" e1="DDI-PubMed.17931461.s5.e0" e2="DDI-PubMed.17931461.s5.e1" /></sentence><sentence text="" /><sentence text="An open label, single center, multiple dose, three period, crossover study was conducted in 24 healthy subjects" /><sentence text=" All subjects received once daily doses of either vildagliptin 100 mg or simvastatin 80 mg or the combination for 7 days with an inter-period washout of 7 days"><entity charOffset="50-62" id="DDI-PubMed.17931461.s8.e0" text="vildagliptin" /></sentence><sentence text=" Plasma levels of vildagliptin, simvastatin, and its active metabolite, simvastatin beta-hydroxy acid (major active metabolite of simvastatin) were determined using validated LC/MS/MS methods"><entity charOffset="18-30" id="DDI-PubMed.17931461.s9.e0" text="vildagliptin" /><entity charOffset="32-43" id="DDI-PubMed.17931461.s9.e1" text="simvastatin" /><entity charOffset="72-101" id="DDI-PubMed.17931461.s9.e2" text="simvastatin beta-hydroxy acid" /><entity charOffset="130-141" id="DDI-PubMed.17931461.s9.e3" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.17931461.s9.e0" e2="DDI-PubMed.17931461.s9.e0" /><pair ddi="false" e1="DDI-PubMed.17931461.s9.e0" e2="DDI-PubMed.17931461.s9.e1" /><pair ddi="false" e1="DDI-PubMed.17931461.s9.e0" e2="DDI-PubMed.17931461.s9.e2" /><pair ddi="false" e1="DDI-PubMed.17931461.s9.e0" e2="DDI-PubMed.17931461.s9.e3" /><pair ddi="false" e1="DDI-PubMed.17931461.s9.e1" e2="DDI-PubMed.17931461.s9.e1" /><pair ddi="false" e1="DDI-PubMed.17931461.s9.e1" e2="DDI-PubMed.17931461.s9.e2" /><pair ddi="false" e1="DDI-PubMed.17931461.s9.e1" e2="DDI-PubMed.17931461.s9.e3" /><pair ddi="false" e1="DDI-PubMed.17931461.s9.e2" e2="DDI-PubMed.17931461.s9.e2" /><pair ddi="false" e1="DDI-PubMed.17931461.s9.e2" e2="DDI-PubMed.17931461.s9.e3" /></sentence><sentence text=" Pharmacokinetic and statistical analyses were performed using WinNonlin and SAS, respectively"><entity charOffset="63-72" id="DDI-PubMed.17931461.s10.e0" text="WinNonlin" /><entity charOffset="77-80" id="DDI-PubMed.17931461.s10.e1" text="SAS" /><pair ddi="false" e1="DDI-PubMed.17931461.s10.e0" e2="DDI-PubMed.17931461.s10.e0" /><pair ddi="false" e1="DDI-PubMed.17931461.s10.e0" e2="DDI-PubMed.17931461.s10.e1" /></sentence><sentence text="" /><sentence text="The 90% confidence intervals of C(max) and AUC(tau) of vildagliptin, simvastatin, and simvastatin beta-hydroxy acid were between 80 and 125% (bioequivalence range) when vildagliptin and simvastatin were admin istered alone and in combination"><entity charOffset="55-67" id="DDI-PubMed.17931461.s12.e0" text="vildagliptin" /><entity charOffset="69-80" id="DDI-PubMed.17931461.s12.e1" text="simvastatin" /><entity charOffset="86-115" id="DDI-PubMed.17931461.s12.e2" text="simvastatin beta-hydroxy acid" /><entity charOffset="169-181" id="DDI-PubMed.17931461.s12.e3" text="vildagliptin" /><entity charOffset="186-197" id="DDI-PubMed.17931461.s12.e4" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.17931461.s12.e0" e2="DDI-PubMed.17931461.s12.e0" /><pair ddi="false" e1="DDI-PubMed.17931461.s12.e0" e2="DDI-PubMed.17931461.s12.e1" /><pair ddi="false" e1="DDI-PubMed.17931461.s12.e0" e2="DDI-PubMed.17931461.s12.e2" /><pair ddi="false" e1="DDI-PubMed.17931461.s12.e0" e2="DDI-PubMed.17931461.s12.e3" /><pair ddi="false" e1="DDI-PubMed.17931461.s12.e0" e2="DDI-PubMed.17931461.s12.e4" /><pair ddi="false" e1="DDI-PubMed.17931461.s12.e1" e2="DDI-PubMed.17931461.s12.e1" /><pair ddi="false" e1="DDI-PubMed.17931461.s12.e1" e2="DDI-PubMed.17931461.s12.e2" /><pair ddi="false" e1="DDI-PubMed.17931461.s12.e1" e2="DDI-PubMed.17931461.s12.e3" /><pair ddi="false" e1="DDI-PubMed.17931461.s12.e1" e2="DDI-PubMed.17931461.s12.e4" /><pair ddi="false" e1="DDI-PubMed.17931461.s12.e2" e2="DDI-PubMed.17931461.s12.e2" /><pair ddi="false" e1="DDI-PubMed.17931461.s12.e2" e2="DDI-PubMed.17931461.s12.e3" /><pair ddi="false" e1="DDI-PubMed.17931461.s12.e2" e2="DDI-PubMed.17931461.s12.e4" /><pair ddi="false" e1="DDI-PubMed.17931461.s12.e3" e2="DDI-PubMed.17931461.s12.e3" /><pair ddi="false" e1="DDI-PubMed.17931461.s12.e3" e2="DDI-PubMed.17931461.s12.e4" /></sentence><sentence text=" These data indicate that the rate and extent of absorption of vildagliptin and simvastatin were not affected when co-administered, nor was the metabolic conversion of simvastatin to its active metabolite"><entity charOffset="63-75" id="DDI-PubMed.17931461.s13.e0" text="vildagliptin" /><entity charOffset="80-91" id="DDI-PubMed.17931461.s13.e1" text="simvastatin" /><entity charOffset="168-179" id="DDI-PubMed.17931461.s13.e2" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.17931461.s13.e0" e2="DDI-PubMed.17931461.s13.e0" /><pair ddi="false" e1="DDI-PubMed.17931461.s13.e0" e2="DDI-PubMed.17931461.s13.e1" /><pair ddi="false" e1="DDI-PubMed.17931461.s13.e0" e2="DDI-PubMed.17931461.s13.e2" /><pair ddi="false" e1="DDI-PubMed.17931461.s13.e1" e2="DDI-PubMed.17931461.s13.e1" /><pair ddi="false" e1="DDI-PubMed.17931461.s13.e1" e2="DDI-PubMed.17931461.s13.e2" /></sentence><sentence text=" All treatments were safe and well tolerated in this study" /><sentence text="" /><sentence text="The pharmacokinetics of vildagliptin, simvastatin, and its active metabolite were not altered when vildagliptin and simvastatin were co-administered"><entity charOffset="24-36" id="DDI-PubMed.17931461.s16.e0" text="vildagliptin" /><entity charOffset="38-49" id="DDI-PubMed.17931461.s16.e1" text="simvastatin" /><entity charOffset="99-111" id="DDI-PubMed.17931461.s16.e2" text="vildagliptin" /><entity charOffset="116-127" id="DDI-PubMed.17931461.s16.e3" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.17931461.s16.e0" e2="DDI-PubMed.17931461.s16.e0" /><pair ddi="false" e1="DDI-PubMed.17931461.s16.e0" e2="DDI-PubMed.17931461.s16.e1" /><pair ddi="false" e1="DDI-PubMed.17931461.s16.e0" e2="DDI-PubMed.17931461.s16.e2" /><pair ddi="false" e1="DDI-PubMed.17931461.s16.e0" e2="DDI-PubMed.17931461.s16.e3" /><pair ddi="false" e1="DDI-PubMed.17931461.s16.e1" e2="DDI-PubMed.17931461.s16.e1" /><pair ddi="false" e1="DDI-PubMed.17931461.s16.e1" e2="DDI-PubMed.17931461.s16.e2" /><pair ddi="false" e1="DDI-PubMed.17931461.s16.e1" e2="DDI-PubMed.17931461.s16.e3" /><pair ddi="false" e1="DDI-PubMed.17931461.s16.e2" e2="DDI-PubMed.17931461.s16.e2" /><pair ddi="false" e1="DDI-PubMed.17931461.s16.e2" e2="DDI-PubMed.17931461.s16.e3" /></sentence><sentence text="" /></document>